Human mitochondrial pyrroline-5-carboxylate reductase (PYCR) is a house-keeping enzyme that catalyzes the reduction of Δ1-pyrroline-5-carboxylate to proline. This enzymatic cycle plays pivotal roles in amino acid metabolism, intracellular redox potential and mitochondrial integrity. Here, we hypothesize that PYCR1 might be a novel prognostic biomarker and therapeutic target for breast cancer. In this study, breast cancer tissue samples were obtained from Zhejiang University (ZJU set). Immunohistochemistry analysis was performed to detect the protein level of PYCR1, and Kaplan-Meier and Cox proportional analyses were employed in this outcome study. The prognostic significance and performance of PYCR1 mRNA were validated on 13 worldwide independent microarray data sets, composed of 2500 assessable breast cancer cases. Our findings revealed that both PYCR1 mRNA and protein expression were significantly associated with tumor size, grade and invasive molecular subtypes of breast cancers. Independent and pooled analyses verified that higher PYCR1 mRNA levels were significantly associated with poor survival of breast cancer patients, regardless of estrogen receptor (ER) status. For in vitro studies, inhibition of PYCR1 by small-hairpin RNA significantly reduced the growth and invasion capabilities of the cells, while enhancing the cytotoxicity of doxorubicin in breast cancer cell lines MCF-7 (ER positive) and MDA-MB-231 (ER negative). Further population study also validated that chemotherapy significantly improved survival in early-stage breast cancer patients with low PYCR1 expression levels. Therefore, PYCR1 might serve as a prognostic biomaker for either ERpositive or ER-negative breast cancer subtypes and can also be a potential target for breast cancer therapy.
Background
Human pyrroline-5-carboxylate reductase (PYCR or P5CR, EC1.5.1.2) catalyzes the final step in the conversion of Δ1-pyrroline-5-carboxylate (P5C) to proline with concomitant oxidation of NAD(P)H to NAD(P) + (1) . Three human PYCR isoenzymes have been identified: PYCR1 (chromosome 17q25.3), PYCR2 (1q42.13) and PYCRL (8q24.3) (2,3). PYCR1 (319aa) and PYCR2 (320aa) have high similarity in amino acid sequence (84%), whereas pyrroline-5-carboxylate reductase-like (PYCRL) protein is only 45% similar to the other two forms (4) . PYCR1 and PYCR2 proteins are both localized in the mitochondria, where the bulk of metabolic reactions take place to support cellular functions and generate reactive oxygen species (5) . PYCR1 demonstrates an ability to protect cells from mitochondrial fragmentation upon oxidative stress (6) . PYCRL protein is primarily located in the cytoplasm, exclusively linked to the conversion of ornithine to proline (3) . Since our preliminary data showed that PYCRL did not significantly impact the outcome of breast cancer, we did not investigate PYCRL in detail in this study. The enzymedependent P5C/proline redox cycle dramatically affects cellular energetic, physiological (6) (7) (8) and pathological (9, 10) processes through the transfer of oxidizing and reducing potential. Our recent studies highlighted that PYCR interacts with RRM2B, a subunit of ribonucleotide reductase (11) . Ribonucleotide reductase catalyzes the conversion of ribonucleoside diphosphate to deoxyribonucleoside diphosphate, a rate-limiting step in the de novo synthesis of deoxyribonucleotide. Low expression of RRM2B has been linked to poor survival in colorectal cancer (12) . Recently, we found that silencing both PYCR1 and PYCR2 reduces the anti-oxidation activity of RRM2B (11) . Overexpression of PYCR1 mRNA, but not PYCR2 or PYCRL, has been reported by DNA microarray data analysis in various types of carcinoma (13) (14) (15) , such as lung cancer, colon cancer and liver cancer. Therefore, it would be valuable to investigate the clinical significance of PYCR1 for cancer treatment.
Breast cancer is one of the most common malignant cancers among females in the world (16, 17) , with approximately 1 million new cases each year. Multiple oncogenes, tumor suppressor genes, sex steroid hormones and their receptors are involved in the genesis and development of breast cancer. Individual breast cancers have similar histopathologic appearances, but they show tremendous variation in clinical outcomes (18, 19) . Breast cancer is a heterogeneous tumor, and there are a variety of subtypes with different biological behaviors and clinicopathologic features that can lead to markedly different prognoses. Currently, therapeutic protocols are not solely dependent on traditional clinicopathological features like age, menopausal status, tumor size, lymph node involvement, distant metastasis, histological grade and histological type. Genetic variations can also help physicians treat patients individually and precisely. Standard protocols using estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (Her2) are included in American Society of Clinical Oncology (ASCO) and College of American Pathologists (CAP) guidelines. These markers [ER, PR, Her2 and marker of proliferation Ki67 (MKI67)] have been widely used to classify breast cancers into four major molecular subtypes-basal-like (or triple negative; ER−, PR− and Her2−), HER2 positive (ER−, Her2+), Luminal A (ER+, MKI67−) and Luminal B (ER+, MKI67+) (20) . This classification of breast cancers has been used to select the appropriate therapeutic regimen. However, personalized precision medicine for breast cancer remains an undeveloped field. More targets and corresponding inhibitors need to be explored to improve treatment efficacy and reduce adverse side effects. Here, we hypothesize that PYCR1/PYCR2 might be driver genes for tumorigenesis and could serve as prognostic biomarkers of breast cancer and/ or therapeutic targets in cancer treatment.
In this study, we investigated the relationships between expression of PYCR1/PYCR2 and differentiation, proliferation and invasion of breast cancer. We found PYCR1, but not PYCR2, significantly enhanced the aggressiveness of breast cancer. In addition, outcome analysis consistently demonstrated that PYCR1, rather than PYCR2, was significantly associated with poor survival of breast cancer patients. Prognostic validations for PYCR1 were conducted on worldwide large-scale gene expression data sets individually and in a pooled manner. PYCR1 expression was significantly correlated with poorer survival in a dose-dependent manner in either ER-positive or ER-negative breast cancers. Inhibition of PYCR1 could significantly enhance the cytotoxicity of doxorubicin on breast cancer cells.
Methods

Cell culture and chemicals
Breast cancer cells, MCF-7 and MDA-MB-231, were obtained from American Type Culture Collection (ATCC, Manassas, VA) in June 2011 and September 2013. Frozen aliquots were stored in liquid nitrogen vapor phase, and cells were cultured for no longer than 6 months after thawing. Cell lines were authenticated by ATCC before delivery and not reauthenticated in our laboratory. Cells were cultured in Dulbecco's modification of Eagle's medium (Mediatech, Inc., Manassas, VA) supplemented with 10% fetal bovine serum (Omega Scientific, Inc., Tarzana, CA) and penicillin and streptomycin (Thermo Fisher Scientific Inc.). All cells were incubated at 37°C and 5% CO2 in a humidified incubator. Doxorubicin (or adriamycin) was obtained from the City of Hope Pharmacy (Duarte, CA).
Small-hairpin RNA plasmids and stable transfectants construction
Lentiviral pLKO.1 vectors (GE Healthcare Dharmacon Inc., Lafayette, CO) were used to express small-hairpin RNA (shRNA). Lentiviral pLKO.1/TRC, sh-PYCR1 and sh-PYCR2 vectors were purchased from GE Healthcare Dharmacon, Inc. The target sequence of pLKO.1/TRC-PYCR1 (TRCN0000038980) was CCCTTCATCCTGGATGAAAT, and pLKO.1/TRC-PYCR2 (TRCN0000046369) was CTGTCGGCTCACAAGATAATA. Lentiviruses were generated as described previously (11) . MCF-7 and MDA-MB-231 cells were transduced with the lentivirus shRNAs and selected with 2 µg/ml puromycin (Sigma-Aldrich) prior to all assays.
Western blot analysis
Procedures for immunoblotting were derived from our previous reports (21, 22) . Briefly, cells were lysed in RIPA buffer (150 mM sodium chloride, 1% NP-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate and 50 mM Tris, pH 8.0), and protein was quantified by BCA assay (Thermo Fisher Scientific). Proteins separated on 10% polyacrylamide gel were transferred to polyvinylidene difluoride membranes (Millipore, Billerica, MA) and detected using antibodies to PYCR1 (Abgent, Inc.) and PYCR2 (LifeSpan BioSciences, Inc.).
In vitro invasion assay
The invasion ability of cancer cells is described as the movement of cells through extracellular matrices. Details of the invasion assay are described in our previous publication (23 To normalize the mRNA expression levels among these data sets, we re-stratified all PYCR1 scores and other related genes into four grades (Q1, Q2, Q3 and Q4) based on the percentile for each data set. Expression levels less than the median value were regarded as PYCR1-low (Q1 + Q2); expression levels greater or equal to the median were designated as PYCR1-high (Q3 + Q4).
ZJU set (multiple-tissue array set)
Details of this set have been described in our previous studies (37, 38) . The protocol for the use of human tissues was reviewed and approved by the Institutional Review Board of Second Affiliated Hospital of Zhejiang University. All patients provided written informed consent for scientific research of leftover tissue samples. All eligible participants underwent modified radical mastectomy, and the primary tumor samples were obtained from surgical specimens. Patients were not included from the data set if they fit any of the exclusion criteria: (i) no informed consent obtained, (ii) presence of multiple cancers, (iii) lack of histological diagnosis and (iv) no follow-up information. After applying the selection criteria, a total of assessable 139 breast cancer patients who were diagnosed from 2002 to 2006 were enrolled in the ZJU set (Supplementary Table 2 , available at Carcinogenesis Online). All recruited patients were Chinese females with a median age of 50 years (range: 20-84 years). Pathoclinical and demographic data were collected from hospital records. After surgery, all patients in the ZJU set were followed up twice a year until September 2010. The PFS time was defined as the time from initial surgery until tumor recurrence, including local relapse and metastasis (PFS event). The OS time period was defined as the time from initial surgery to the date the patient was last seen. Only deaths caused by breast cancer related events, such as metastasis or local relapse of breast cancer, were considered as OS events. Otherwise, these cases were defined as censored end (no OS event). Median follow-up time was 73.6 months (range: 8.9-104.9 months) for OS and 71.2 months (range: 2.5-104.9 months) for PFS.
Gene set enrichment analysis
The detailed gene set enrichment analysis (GSEA) protocol can be obtained from the Broad Institute Gene Set Enrichment Analysis website (www.broad.mit.edu/gsea) and related references (39) . The GSEA software v2.0.13 was run using a JAVA 7.0 platform. The data set (.gct) and phenotype label (.cls) files were created and loaded into GSEA software, and gene sets were downloaded from the Broad Institute website. The number of permutations was set to 1000, and the phenotype label was PYCR1-high versus PYCR1-low. The ranked-list metric was generated by calculating the signal-to-noise ratio, which is based on the difference of means scaled according to the standard deviation.
Quantitative immunohistochemistry assays
All primary breast cancers specimens in the ZJU set were assembled and built into a multiple-tissue array as described previously (23) . The PYCR1 antibody was previously generated, selected and tested in our lab. Antibodies against HER2 (Clone: A0485), ER (Clone: SP1), PR (Clone: PgR636) and Ki67 (Clone: MIB-1) were purchased from Dako company, and the p53 antibody (Clone: DO-7) was purchased from Vector Lab. The previously described deparaffinization and immunohistochemistry (IHC) staining protocol was used to stain the proteins in tissue sections from the multiple-tissue array (23) . The cut-off values for HER2, ER and PR positivity were based on previous reports (40, 41) . According to the above IHC staining, all of the participants were classified into four intrinsic subtypes: Luminal A, Luminal B, HER2-positive and basal-like triple negative breast cancer (TNBC) (42) . The specificity and efficacy of PYCR1 antibody was taken into consideration. In western blot analysis, only one dominant band was visualized, and its signal was significantly decreased after treatment with sh-PYCR1. In IHC staining, PYCR1 showed a spaghetti-like pattern in the cytoplasm of cancer cells, which is consistent with other mitochondrial markers' staining patterns. Immunoreactivity in the cytoplasm was scored according to the percentage and intensity of staining. The staining intensity was scored as 0: negative, 1: weak, 2: moderate and 3: strong. The IHC staining in each cell varied, as a result of the heterogeneity of cancer cells. In our scoring system, samples were included for consideration if >10% of the whole cells had positive staining. Finally, the expression levels of the proteins were divided into four subgroups: negative (−), weakly positive (+ −), positive (+) and strongly positive (++). In Cox analysis, (−) and (+ −) were defined as PYCR1-low, whereas (+) and (++) were defined as PYCR1-high.
To normalize all IHC results, samples were photographed under controlled conditions, such as exposure time, brightness, contrast, saturation and sharpness by using same digital camera. Moreover, four typical staining pictures were selected to represent negative (−), weakly positive (+ −), positive (+) and strongly positive (++). Each IHC picture was given a proper score after being shown alongside the four standard pictures. To avoid observer bias, all the slides were evaluated independently by two different observers with training in pathology in a double-blinded manner. Discrepancies were jointly reviewed by the two readers, and missing samples were left blank.
Data management and statistical methods
The database was downloaded, converted, constructed and managed using MS-Excel. JMP 10.0 software (SAS Institution, Cary, NC) was used for general statistical analysis. Group comparisons for continuous data were performed using t-tests for independent means or one-way analyses of variance. Categorical variables were compared using χ 2 analysis, Fisher's exact test or the binomial test of proportions. Kaplan-Meier analysis and Cox proportional hazard models were used to analyze OS and PFS. Since there was no patient with distant metastatic breast cancer in ZJU set, all patients were included in PFS analysis. Multivariate Cox analysis was applied to adjust for covariate effects, and stratification analysis was used to reduce the potential confounding effect on estimation of hazard ratio (HR). Missing data was coded and excluded from the analysis.
Results
PYCR1 is associated with poor differentiation and aggressive phenotypes of breast cancer
The expression data of PYCR1 could be obtained for all collected data sets, but PYCR2 gene expression data were only included on GSE1456, GSE4922, GSE22219, GSE10855, GSE2226, GSE24450, GSE53031 and GSE58812 sets. To compare the clinical relevance between PYCR1 and PYCR2, we combined these eight data sets, termed as pooled dataset1. Analysis results showed that mRNA expression levels of PYCR1 was significantly associated with tumor size and higher grade of breast cancer ( Figure 1A ), but PYCR2 had no clinical relevance ( Figure 1B) . In the GSE1456 set, mRNA expression levels of PYCR1 were significantly higher in aggressive molecular subtypes including Luminal B, HER2-positive and basal-like breast cancer ( Figure 1C, left) . However, the PYCR2 mRNA expression levels were significantly lower in the basallike subgroup, when compared with the Luminal A and Luminal B subgroups ( Figure 1C, right) . In pooled dataset1, the percentage of PYCR1-high cases in subtypes of normal-like, Luminal A, A further GSEA analysis indicated that high-expression of PYCR1 significantly enriched the gene signatures related to undifferentiation and proliferation in the GSE1456 data set ( Figure 1D ). The normalized enrichment score (NES) were 2.50 and 2.65, respectively (P < 0.0001). The correlation between PYCR1 and poor differentiation and tumor growth were further validated.
In addition to GSEA, the clinical relevance of PYCR1 protein levels was further validated based on IHC staining of the multiple-tissue array from ZJU. Representative IHC results of PYCR1 are shown on Figure 1E . It was visualized that PYCR1 expression was associated with differentiation of breast cancer. Analysis indicated that PYCR1 protein levels correlated with increased tumor size (P = 0.058) and significantly and positively associated with Elston grade (P = 0.011). This phenomenon was observed in ER-negative (P = 0.006), Her2-positive (P = 0.002) and MKI67-positive (P < 0.001) breast cancer cases. The expression levels of PYCR1 differed in each molecular subtype (P = 0.002) ( Figure 1F ). Similar findings were also seen from the pooled analysis of worldwide gene expression data sets (Supplementary Table 2 , available at Carcinogenesis Online). However, PYCR1 did not associate with stem/progenitor markers CD44+/CD24− in ZJU set.
All of the above findings validated that both mRNA and protein levels of PYCR1 were significantly associated with aggressive phenotypes in breast cancer.
Prognostic significance of PYCR1 for breast cancers
Since PYCR1 was associated with undifferentiation and aggressive phenotypes of breast cancer, the expression of PYCR1 may be associated with poor outcomes in breast cancer. To address this hypothesis, outcome analysis was conducted on public microarray gene expression data sets. Here, we re-categorized participants of each data sets into four subgroups (Q1, Q2, Q3 and Q4) according to the expression levels of PYCR1 or PYCR2. To ensure fair comparisons, only data sets with both PYCR1 and PYCR2 expression information were pooled in this analysis. In Figure 2A and B, the mRNA levels of PYCR1, rather than PYCR2, significantly impacted poor PFS of breast cancer. As PYCR1 levels increased, PFS decreased in a dose-dependent manner. The prognostic significance of PYCR1 was further analyzed in all collected gene expression data sets. Pooled analysis confirmed PYCR1 has a significant impact on poor OS and PFS of breast cancer ( Figure 2C and D) .
Further survival analysis was conducted for each of data sets by using uni-and multiple Cox proportional hazard analysis. The results are listed on Table I . Q1, the lowest expression subgroup, was set as the relative point of reference. Mostly, the HR of PYCR1 for OS and PFS increased as PYCR1 expression levels increased. Particularly in higher PYCR1 levels (Q4), the significance could be seen in almost all data sets. The overall pooled analysis indicated that the HR of higher PYCR1 (Q4) for OS and PFS were 1.51 [95% confidence interval (CI): 1.11-2.07] and 1.79 (95% CI: 1.46-2.20), respectively.
The prognostic significance of PYCR1 protein was also evaluated in the ZJU set. Kaplan-Meier analysis for OS and PFS are displayed in Figure 2E and F. In multivariate Cox proportional hazard analysis, the HR of PYCR1 for OS and PFS were 3.44 (95% CI: 1.06-15.68, P = 0.037) and 2.49 (95% CI: 0.98-7.63, P = 0.055) after adjusting for age, adjuvant chemotherapy and hormone therapy. It was confirmed that either mRNA or protein PYCR1 expression significantly impacted the poor survival of breast cancer.
Prognostic performance of PYCR1 in ER-positive and ER-negative breast cancers
ER-negative breast cancers (including the HER2-positive and TNBC subtypes) have a poor prognosis (43) . Our previous analysis found that PYCR1 has higher expression levels in ER-negative breast cancers. Here, further stratified Kaplan-Meier analysis of the pooled data revealed that PYCR1 mRNA levels were significantly associated with poor OS and PFS in both ER-negative and ER-positive breast cancers ( Figure 3A and B) . The prognostic significance of PYCR1 was also analyzed among molecular subtypes. Due to insufficient sample size, PYCR1 did not show a significant impact on patient survivability based on molecular subtype.
The prognostic performance of PYCR1, but not PYCR2, was comparable with tumor size and lymph node involvement. However, Elston grade ( Figure 3C and D) had better prognostic capabilities than PYCR1. This scenario could be seen on both ER-positive and ER-negative subsets. The above findings suggest that PYCR1 could serve as a prognostic biomarker to predict poor outcome in either ER-positive or ER-negative breast cancers.
Inhibition of PYCR1 causes growth retardation and invasion reduction in breast cancer cells
To determine whether inhibition of PYCR1 could reduce the development of breast cancer in vitro, shRNA was used to downregulate expression of PYCR1 in ER-negative breast cancer cell line MDA-MB-231 and in ER-positive breast cancer cell line MCF-7 ( Figure 4A ). Expression plasmids sh-NS and sh-PYCR2 plasmids were employed as controls. Table 1 . Continued indicated that sh-PYCR1 dramatically reduced the protein level of PYCR1 in both MDA-MB-231 and MCF-7. It also reduced the PYCR2 expression level in MDA-MB-231, but only slightly in MCF-7. As a control, sh-PYCR2 specifically decreased the expression of PYCR2 but had no significant effect on PYCR1 for both cell lines. Western blot analysis showed that E-cadherin increased in sh-PYCR1 transfectants in both MDA-MB-231 and MCF-7. The N-Cadherin could not be visualized by western blot because of low expression in both cell lines, which is consistent with other studies.
After reducing PYCR1/PYCR2 in MCF-7 and MDA-MB-231, expression levels of Akt, p-Akt, ERK and p-ERK levels were measured ( Figure 4A ). The levels of Akt and p-Akt did not change significantly after PYCR1 reduction, whereas ERK and p-ERK levels slightly decreased with inhibition of PYCR1. On the other hand, sh-PYCR2 could not reduce the expression levels of ERK and p-ERK. Inhibition of PYCR1 significantly retarded cell growth of both MDA-MB-231 and MCF-7 ( Figure 4B ), but sh-PYCR2 showed no effect on cell growth for either cell line.
A gelatin zymography assay was employed to examine the MMP protein activity under inhibition of PYCR1 and PYCR2 ( Figure 4C ). It indicated that inhibition of PYCR1, rather than PYCR2, could eventually inhibit MMP9 activity in both MDA-MB-231 and MCF-7 cancer cells. The invasion assay also indicated that sh-PYCR1 could reduce invasive cells from 361.8 ± 61.5 per field (sh-NS) to 122.2 ± 19.6 per field (sh-PYCR1) in MDA-MB-231 cells (student t = 12.3, P < 0.001) ( Figure 4D ). However, sh-PYCR2 seemed to upregulate the invasion ability of MDA-MB-231 cells, as well as in MCF-7 cells.
These findings suggested that inhibition of PYCR1, but not PYCR2, could significantly reduce the growth and invasive ability of cancer cells in both MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) cell lines.
Reduction of PYCR1 sensitizes chemotherapy in breast cancer
Doxorubicin (also known as adriamycin) is one of most common therapeutic agents used for breast cancer treatment. Doxorubicin is known to augment free-radical generation and lipid peroxidation process in vitro (44) . Published literature reports that proline, a product of PYCR1/2, has the potential to scavenge free radicals in vitro (45) . Therefore, our hypothesis is that the elimination of PYCR1 might sensitize cells to doxorubicin through a proline-free radical pathway. To address this hypothesis, we transfected sh-PYCR1 and sh-PYCR2 into MCF-7 and MDA-MB-231 cells to reduce the expression of PYCR1 and PYCR2, respectively ( Figure 5A and B) . Then, we tested the cytotoxicity of doxorubicin on the above transfectants. Here, each cytotoxicity curve was normalized with a blank control without doxorubicin. Results revealed that inhibition of PYCR1, rather than PYCR2, significantly enhanced the chemosensitivity to doxorubicin in both MCF-7 and MDA-MB-231 cells. The in vitro experiments showed that low expression levels of PYCR1, but not PYCR2, enhance cancer sensitivity to chemotherapy agents.
Chemotherapy is generally administered to patients with advanced stages of breast cancer (stage III or IV). For stage II breast cancer, application of chemotherapy depends on tumor size, grade and other indicators. In these cases, a therapeutic biomarker would be very helpful for chemotherapy selection. Our population study demonstrated that chemotherapy significantly improved the survival of stage IIa breast cancer patients with PYCR1-low expression in NKI data set (log-rank P = 0.040; HR = 0.33; 95% CI: 0.10-0.91) ( Figure 5C ), but not in the PYCR1-high subgroup (log-rank P = 0.524) ( Figure 5D ). This phenomenon was not observed in outcome analysis when patients were stratified by PYCR2-high and PYCR2-low. The result was consistent to that from the above cell culture-based experiment.
These findings suggest elimination of PYCR1, not PYCR2, can significantly enhance the cytotoxicity of doxorubicin in both MCF-7 and MDA-MB-231 cancer cells. PYCR1 can also be used as a therapeutic target and can serve as a biomarker for chemotherapy selection for breast cancer treatment.
Discussion
PYCR1 was expressed significantly higher in molecular subtypes with poor outcome, which include basal-like, HER2-positive and Luminal B (Figure 1, Supplementary Table 2 , available at Carcinogenesis Online). Despite the diverse proportions of molecular subtypes, consistent results were seen in data sets collected from Asia (ZJU set), Europe (GSE1456, GSE22219, GSE53031 and NKI sets) and North America (GSE22226 and GSE41119 sets). Overall, higher mRNA and protein levels of PYCR1, rather than PYCR2, were significantly associated with breast cancers with higher proliferation, poor differentiation and poorer prognosis for patients. Further analysis revealed PYCR1 correlated with poor survival for both ER-positive and ER-negative breast cancers. Inhibition of PYCR1, but not PYCR2, could significantly reduce the growth and invasive ability of cancer cells in both MCF-7 (ER-positive) and MDA-MB-231 (ER-negative) cell lines. These findings suggest that PYCR1 might be a driver gene in breast cancers. Moreover, PYCR1 could serve as an independent prognostic biomarker to predict poor survival for both ER-positive and ER-negative breast cancers.
It has been suggested that cancer cells might depend on high levels of PYCR1 to support cell growth and confer resistance to oxidative stress for cell survival (11) . PYCR1 was one of the most frequently overexpressed metabolic genes across 1981 tumor samples spanning 19 cancer types (46) . It was reported that the oncogenic transcription factor c-MYC could upregulate glutaminase to convert glutamine to glutamate to fuel growth and proliferation of cancer cells. MYC also markedly increased the enzymes of proline biosynthesis from glutamine, including P5C synthase and PYCR1 (47) . Meanwhile, c-MYC as well as PI3K markedly decrease the expression of proline dehydrogenase (PRODH; also known as proline oxidase) through inhibiting miR-23b microRNA (47) . Proline is synthesized from either glutamate or ornithine; both are converted to pyrroline-5-carboxylate (P5C). PYCR1 and PYCR2 are primarily involved in the conversion of glutamate to proline in mitochondria, but PYCRL is linked to convert ornithine to proline in cytoplasm (3) . Proline is the only secondary proteinogenic amino acid (1), which supplies substrates for protein synthesis in cancer cell proliferation.
The functional role of proline metabolism in redox regulation is described as a 'proline cycle' or 'redox shuttle' ( Figure 5E ). The interconversions of proline and its oxidized congener P5C transfer redox equivalents between the mitochondria and the cytosol (48) (Figure 5E , left side). PRODH generates proline-dependent reactive oxygen species (ROS) to activate Akt and induce apoptosis (49) (50) (51) (52) (53) . Proline-derived electrons enter the mitochondrial electron transport chain through FAD; the electrons are then transferred to CoQ at complex III. Some of the electrons can be used to generate ATP, which reduce oxygen to generate superoxide (47, 54) . In human cells, proline is a potent antioxidant that protects cells from oxidative stress-related apoptosis, which requires the activity of PRODH (55) . Inhibition of PYCR1 and induction of PRODH by oxidative stress decrease the proline level in mitochondria, which can dramatically enhance ROS generation ( Figure 5E , right side). Our in vitro studies demonstrated that the efficacy of doxorubicin was significantly enhanced when PYCR1 expression was inhibited in breast cancer cells ( Figure 5A and B). In population studies, our preliminary analysis also demonstrated that chemotherapy could significantly reduce the risk of relapse in stage IIa breast cancer for PYCR1-low patients (HR = 0.33, 95% CI: 0.09-0.87. n = 69, P = 0.024), but not in PYCR1-high patients (HR = 0.91, 95% CI: 0.45-1.78. n = 73, P = 0.789). This finding further validates that lack of PYCR1 might enhance chemosensitivity of doxorubicin as a breast cancer treatment. Potentially, PYCR1 may serve as a predictive biomarker for stage IIa breast cancer. In addition, specific PYCR1 inhibitors might be used as a sensitizer to enhance chemotherapy efficacy.
The mechanism that explains why only PYCR1, but not PYCR2, plays critical roles on cancer aggressiveness and chemosensitivity remains unknown. A research team reported that the Ki of inhibition by proline for recombinant human PYCR1 and PYCR2 were 0.6 and 0.1 mM, respectively (3). The NADHmediated activity was higher with PYCR2, but not PYCR1. These findings suggest that PYCR2 may be more closely linked to satisfying the proline requirements for proteinogenesis, whereas PYCR1 may be more closely associated with NADH redox cycling. It may also partially explain the different functions between PYCR1 and PYCR2, despite having >80% similarity in protein sequence.
Besides gene expression, many factors (such as quality of medical care, socio-economic class, patients' education levels and compliance) can significantly affect patient survival and outcome. In this study, these biases and confounders were taken into consideration. To control these biases, results were validated individually and in a pooled manner on 13 worldwide multicenter data sets. Pooled analysis could avoid publication bias that might potentially be amplified by meta-analysis. Here, stratification and multivariate analyses were used to reduce potential confounders' effect. Our data showed that high PYCR1 levels impacted poor survival in different populations with varying socio-economic and race backgrounds. Therefore, we believe our data are reproducible and reliable.
There are some limitations in this study. First, we only showed phenomenological findings on the differences between PYCR1 and PYCR2. Detailed mechanisms need to be investigated in our future studies. Second, the sample size of ZJU set is limited; therefore, we were not able to verify if PYCR1 protein levels were correlated with resistance to chemotherapy. Third, doxorubicin is only one of many common chemotherapy agents, so the data yielded from doxorubicin treatment could not fully explain if PYCR1 causes chemotherapy resistance in breast cancer.
Overall, these findings revealed that the mRNA and protein PYCR1 levels were significantly related to the poor outcome in either ER-negative or ER-positive breast cancer. PYCR1 could serve as a prognostic biomarker, therapeutic target and predictive biomarker for breast cancers.
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